Propranolol as first‐line treatment for life‐threatening diffuse infantile hepatic hemangioma: A case report
Giulia Varrasso, Amalia Schiavetti, Silvia Lanciotti, Maria Sapio, Eva Ferrara, Alessandra De Grazia, Anna Clerico – 5 January 2017
Knockout of the primary sclerosing cholangitis‐risk gene Fut2 causes liver disease in mice
Luca Maroni, Simon D. Hohenester, Stan F.J. van de Graaf, Dagmar Tolenaars, Krijn van Lienden, Joanne Verheij, Marco Marzioni, Tom H. Karlsen, Ronald P.J. Oude Elferink, Ulrich Beuers – 5 January 2017 – The etiopathogenesis of primary sclerosing cholangitis is unknown. Genetic variants of fucosyltransferase 2 (FUT2) have been identified in genome‐wide association studies as risk factors for primary sclerosing cholangitis. We investigated the role of Fut2 in murine liver pathophysiology by studying Fut2–/– mice.
Propranolol as first‐line treatment for life‐threatening diffuse infantile hepatic hemangioma: A case report
Giulia Varrasso, Amalia Schiavetti, Silvia Lanciotti, Maria Sapio, Eva Ferrara, Alessandra De Grazia, Anna Clerico – 5 January 2017
The changing face of hepatic encephalopathy: A projection for the next 5 years
Debbie L. Shawcross – 30 December 2016
Mechanisms of portal hypertension: Bench to bedside
Jordi Gracia‐Sancho, Wim Laleman – 30 December 2016
Novel approaches to the treatment of biliary atresia
Yang Li, Jorge A. Bezerra – 30 December 2016
The changing face of hepatic encephalopathy: A projection for the next 5 years
Debbie L. Shawcross – 30 December 2016
A framework to determine when liver transplantation is futile
Jennifer C. Lai – 30 December 2016
Managing encephalopathy in the outpatient setting
Sahaj Rathi, Radha K. Dhiman – 30 December 2016
Treatment of chronic cholestasis: What we know and what we will know?
James L. Boyer – 30 December 2016